NCT02870140 (TALENT) is a NA clinical trial of SUPRAFLEX in Coronary Stenosis, sponsored by ECRI bv.

Who is sponsoring NCT02870140?

NCT02870140 is sponsored by ECRI bv.

What drugs are being tested in NCT02870140?

Interventions in NCT02870140: SUPRAFLEX, XIENCE.

What condition does NCT02870140 study?

NCT02870140 studies Coronary Stenosis.

Is NCT02870140 still recruiting?

NCT02870140 is currently completed. Last updated 17 December 2020.

Last reviewed 2020-12-17 · How we verify

NCT02870140: TALENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent

Completed NA Last updated 17 December 2020

What this trial tests

NA trial testing SUPRAFLEX in Coronary Stenosis in 1,435 participants. Completed in 26 August 2020.

Timeline

21 October 2016

Primary endpoint
20 September 2018

26 August 2020

Quick facts

Lead sponsor	ECRI bv
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	1,435
Start date	21 October 2016
Primary completion	20 September 2018
Estimated completion	26 August 2020
Sites	23 locations across Italy, Netherlands, United Kingdom, Poland, Hungary, Bulgaria, Spain

Drugs / interventions tested

SUPRAFLEX
XIENCE

Conditions studied

Coronary Stenosis — all drugs for Coronary Stenosis →

Sponsor

ECRI bv — full company profile →

Who can join

18 and older, any sex, with Coronary Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to compare the performance of SUPRAFLEX to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease. The patients will be followed through 3 years for major clinical events.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
Zaman A, de Winter RJ, Kogame N, Chang CC, et al · · 2019 · cited 74× · PMID 30827782 · DOI 10.1016/s0140-6736(18)32467-x
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.
de Winter RJ, Zaman A, Hara H, Gao C, et al · · 2022 · cited 19× · PMID 35285804 · DOI 10.4244/eij-d-21-00766
A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?
Grundeken MJ, Beijk MA. · · 2021 · cited 9× · PMID 36277831 · DOI 10.17925/hi.2021.15.2.84
Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials.
Wang R, Kawashima H, Hara H, Gao C, et al · · 2021 · cited 7× · PMID 34666500 · DOI 10.1161/circoutcomes.121.008055

Verify or expand the search:

Other recruiting trials for Coronary Stenosis

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting
NCT05709652 — Impact of Fast-rotation Coronary CT in Patients Undergoing Aortic Stenosis Workup · NA · recruiting
NCT06376630 — Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI · NA · recruiting
NCT04014140 — iFR Guided Coronary Artery Bypass Grafting Surgery · recruiting

Other ECRI bv trials

Trials by the same sponsor.

NCT07276282 — Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction · Phase 3 · recruiting
NCT04854070 — Intravascular Ultrasound Guidance for Complex High-risk Indicated Procedures · NA · active not recruiting
NCT04111770 — The OPTIMAL Randomized Controlled Trial · NA · completed
NCT03851263 — Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion · Phase 4 · withdrawn
NCT03851276 — A Multicentre, Pilot Study to Evaluate the Safety and the Feasibility of Planning and Execution of Surgical Revasculariz · Phase 4 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02870140 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ECRI bv
Last refreshed: 17 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02870140.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing